Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing
Black Friday Get Elite for just $149.00 Claim Now
Market News Market Pulse Stocks News ETF News Crypto News

Eikon Therapeutics, Inc.

Contributing Author

Recent Articles by Eikon Therapeutics, Inc.

8 hours
Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates EIKN -8.40% GlobeNewswire
Nov-02
Eikon Therapeutics to Participate in Multiple Investor Conferences in November EIKN +6.97% GlobeNewswire
Oct-26
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress EIKN -23.69% GlobeNewswire
Oct-23
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress EIKN -11.89% GlobeNewswire
Oct-18
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress EIKN GlobeNewswire
Oct-15
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer EIKN +7.56% GlobeNewswire
Sep-03
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer EIKN GlobeNewswire
Aug-26
Eikon Therapeutics to Participate in Investor Conferences in September 2026 EIKN GlobeNewswire
Aug-18
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald EIKN +11.27% GlobeNewswire
Aug-13
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates EIKN EIKN +6.97% GlobeNewswire
Aug-11
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma EIKN +5.14% GlobeNewswire
Aug-10
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board EIKN GlobeNewswire
Jul-27
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer EIKN +11.01% GlobeNewswire
Jul-20
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress EIKN GlobeNewswire
Jun-25
Eikon Therapeutics to Join the Russell 3000 Index EIKN EIKN +16.24% GlobeNewswire
Jun-08
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors EIKN GlobeNewswire
May-30
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology EIKN GlobeNewswire
May-21
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology EIKN GlobeNewswire
May-11
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates EIKN EIKN +15.88% GlobeNewswire
Mar-30
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates EIKN GlobeNewswire
Feb-04
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering EIKN GlobeNewswire
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)